Ernexa Therapeutics Inc. - 31ERNAWPreferred / convertible
13F holders, Q2 2026 (June 30)6holders +1
1new positions
0sold out
$0.07avg. 13F price*
At the end of Q2 2026, 6 institutions reported holding Ernexa Therapeutics Inc. - 31 (ERNAW) in their 13F filings, up 1 from Q1 2026. 1 opened new positions and 0 sold out. The largest holders were Bleichroeder LP ($143K), Heights Capital Management, Inc. ($29K) and Armistice Capital, LLC ($11K).
- Company
- Ernexa Therapeutics Inc. - 31
- CUSIP
- 114082118
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $4K |
| Exits | 0 | $0 |
All 13F filers, Q1 2026 → Q2 2026: 58,089 shares bought and 4,024,370 shares sold, net −3,966,281 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Bleichroeder LP | — | No change | 2,000,000 | $143K |
| Heights Capital Management, Inc. | — | No change | 400,000 | $29K |
| Armistice Capital, LLC | — | Reduce -96.0% | 160,000 | $11K |
| Clear Street Group Inc. | — | Add +0.1% | 149,499 | $11K |
| Warberg Asset Management LLC | — | Reduce -72.6% | 69,430 | $5K |
| Susquehanna International Group, LLP | — | New | 57,890 | $4K |
"% of holder's portfolio" is ERNAW's weight in each manager's 13F, not the share of Ernexa Therapeutics Inc. - 31 the manager owns.